This company listing is no longer active
Adcock Ingram Holdings Past Earnings Performance
Past criteria checks 3/6
Adcock Ingram Holdings has been growing earnings at an average annual rate of 5.6%, while the Pharmaceuticals industry saw earnings growing at 18.2% annually. Revenues have been growing at an average rate of 5.9% per year. Adcock Ingram Holdings's return on equity is 14.7%, and it has net margins of 8.8%.
Key information
5.55%
Earnings growth rate
8.40%
EPS growth rate
| Pharmaceuticals Industry Growth | 12.39% |
| Revenue growth rate | 5.94% |
| Return on equity | 14.72% |
| Net Margin | 8.80% |
| Last Earnings Update | 30 Jun 2025 |
Recent past performance updates
Recent updates
Adcock Ingram Holdings' (JSE:AIP) Shareholders Will Receive A Bigger Dividend Than Last Year
Aug 27
What Adcock Ingram Holdings Limited's (JSE:AIP) 36% Share Price Gain Is Not Telling You
Jul 24Investors Can Find Comfort In Adcock Ingram Holdings' (JSE:AIP) Earnings Quality
Feb 28Shareholders Will Probably Hold Off On Increasing Adcock Ingram Holdings Limited's (JSE:AIP) CEO Compensation For The Time Being
Nov 13We Think Shareholders Are Less Likely To Approve A Large Pay Rise For Adcock Ingram Holdings Limited's (JSE:AIP) CEO For Now
Nov 17Adcock Ingram Holdings (JSE:AIP) Is Increasing Its Dividend To ZAR1.09
Aug 28Revenue & Expenses Breakdown
How Adcock Ingram Holdings makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 25 | 9,760 | 859 | 2,039 | 0 |
| 31 Mar 25 | 9,689 | 809 | 2,033 | 0 |
| 31 Dec 24 | 9,617 | 760 | 2,026 | 0 |
| 30 Sep 24 | 9,630 | 787 | 2,013 | 0 |
| 30 Jun 24 | 9,643 | 814 | 2,000 | 0 |
| 31 Mar 24 | 9,419 | 844 | 1,995 | 0 |
| 31 Dec 23 | 9,196 | 874 | 1,991 | 0 |
| 30 Sep 23 | 9,164 | 886 | 2,004 | 0 |
| 30 Jun 23 | 9,132 | 898 | 2,017 | 0 |
| 31 Mar 23 | 9,084 | 888 | 2,007 | 0 |
| 31 Dec 22 | 9,037 | 877 | 1,997 | 0 |
| 30 Sep 22 | 8,871 | 839 | 1,976 | 0 |
| 30 Jun 22 | 8,706 | 800 | 1,956 | 0 |
| 31 Mar 22 | 8,535 | 769 | 1,915 | 0 |
| 31 Dec 21 | 8,364 | 737 | 1,874 | 0 |
| 30 Sep 21 | 8,071 | 697 | 1,811 | 0 |
| 30 Jun 21 | 7,777 | 657 | 1,747 | 0 |
| 31 Mar 21 | 7,627 | 636 | 1,729 | 0 |
| 31 Dec 20 | 7,476 | 614 | 1,711 | 0 |
| 30 Sep 20 | 7,411 | 645 | 1,734 | 0 |
| 30 Jun 20 | 7,347 | 676 | 1,757 | 0 |
| 31 Mar 20 | 7,229 | 693 | 1,817 | 0 |
| 31 Dec 19 | 7,112 | 710 | 1,877 | 0 |
| 30 Sep 19 | 7,095 | 700 | 1,876 | 0 |
| 30 Jun 19 | 7,078 | 690 | 1,875 | 0 |
| 31 Mar 19 | 6,974 | 680 | 1,857 | 0 |
| 31 Dec 18 | 6,869 | 671 | 1,838 | 0 |
| 30 Sep 18 | 6,626 | 649 | 1,767 | 0 |
| 30 Jun 18 | 6,383 | 627 | 1,696 | 0 |
| 31 Mar 18 | 6,224 | 605 | 1,644 | 0 |
| 31 Dec 17 | 6,066 | 583 | 1,593 | 0 |
| 30 Sep 17 | 6,001 | 548 | 1,576 | 0 |
| 30 Jun 17 | 5,936 | 512 | 1,559 | 0 |
| 31 Mar 17 | 5,891 | 482 | 1,520 | 0 |
| 31 Dec 16 | 5,847 | 452 | 1,482 | 0 |
| 30 Sep 16 | 5,696 | 411 | 1,463 | 0 |
| 30 Jun 16 | 5,546 | 369 | 1,443 | 0 |
| 31 Mar 16 | 5,407 | 358 | 1,422 | 0 |
| 31 Dec 15 | 5,268 | 348 | 1,401 | 0 |
| 30 Sep 15 | 5,213 | 348 | 1,386 | 0 |
| 30 Jun 15 | 5,159 | 349 | 1,371 | 0 |
| 31 Dec 14 | 4,849 | -858 | 1,446 | 0 |
Quality Earnings: AIP has high quality earnings.
Growing Profit Margin: AIP's current net profit margins (8.8%) are higher than last year (8.4%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: AIP's earnings have grown by 5.6% per year over the past 5 years.
Accelerating Growth: AIP's earnings growth over the past year (5.5%) is below its 5-year average (5.6% per year).
Earnings vs Industry: AIP earnings growth over the past year (5.5%) did not outperform the Pharmaceuticals industry 36.1%.
Return on Equity
High ROE: AIP's Return on Equity (14.7%) is considered low.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/11/12 20:57 |
| End of Day Share Price | 2025/11/04 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2025/06/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Adcock Ingram Holdings Limited is covered by 7 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Marcelle Jankelow | Citigroup Inc |
| Sean Ashton | Deutsche Bank |
| Alex Robert Comer | J.P. Morgan |